Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | RELA | Q04206 | 2/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL656837 | 0.78 | EPHX2 (0.56) | EPHX2SMN1; SMN2ALDH1A1KDM4EGAA | |
| SCHEMBL29541546 | 0.77 | CYP1A2 (0.47) | EPHX2SMN1; SMN2ALDH1A1KDM4EGAA | |
| SCHEMBL6817772 | 0.77 | CYP1A2 (0.47) | EPHX2SMN1; SMN2ALDH1A1KDM4EGAA | |
| SCHEMBL7450169 | 0.75 | CYP1A2 (0.46) | EPHX2SMN1; SMN2ALDH1A1KDM4EGAA | |
| SCHEMBL12681544 | 0.75 | SMN1; SMN2 (0.51) | EPHX2SMN1; SMN2ALDH1A1KDM4EGAA | |
| SCHEMBL6368033 | 0.75 | ALDH1A1 (0.48) | EPHX2SMN1; SMN2ALDH1A1KDM4EGAA | |
| SCHEMBL29503805 | 0.75 | SMN1; SMN2 (0.51) | EPHX2SMN1; SMN2ALDH1A1KDM4EGAA | |
| SCHEMBL2310167 | 0.75 | CYP1A2 (0.46) | EPHX2SMN1; SMN2ALDH1A1KDM4EGAA | |
| SCHEMBL4053984 | 0.75 | EPHX2 (0.49) | EPHX2SMN1; SMN2ALDH1A1KDM4EGAA | |
| SCHEMBL1957859 | 0.75 | CYP1A2 (0.46) | EPHX2SMN1; SMN2ALDH1A1KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111217762-B | Polyhalogenated 5- (2-hydroxyphenyl) isoxazole compound and preparation method and application thereof | 华中师范大学 | 2021-08-20 | — | — | CN | claimed |
| CN-111217762-A | Polyhalogenated 5- (2-hydroxyphenyl) isoxazole compound and preparation method and application thereof | 华中师范大学 | 2020-06-02 | — | — | CN | claimed |
| EP-4069680-C0 | PROCESS FOR SYNTHESIS OF A 2-(5-ISOXAZOLYL)-PHENOL | FMC CORP (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-4069680-B1 | PROCESS FOR SYNTHESIS OF A 2-(5-ISOXAZOLYL)-PHENOL | FMC CORP (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-4069680-B1 | PROCESS FOR SYNTHESIS OF A 2-(5-ISOXAZOLYL)-PHENOL | FMC CORP (US) | 2026-03-25 | — | — | EP | disclosed |
| US-12291525-B2 | Process for synthesis of a 2-(5-isoxazolyl)-phenol | FMC CORPORATION (US) | 2025-05-06 | — | — | US | disclosed |
| US-12291525-B2 | Process for synthesis of a 2-(5-isoxazolyl)-phenol | FMC CORPORATION (US) | 2025-05-06 | — | — | US | disclosed |
| CN-114746406-B | Method for synthesizing 2- (5-isoxazolyl) -phenol | FMC公司 | 2024-11-01 | — | — | CN | disclosed |
| CN-114746406-B | Method for synthesizing 2- (5-isoxazolyl) -phenol | FMC公司 | 2024-11-01 | — | — | CN | disclosed |
| CN-118290443-A | Chromone heterocyclic compound, and preparation method and application thereof | 中国科学院上海药物研究所 | 2024-07-05 | — | — | CN | disclosed |
| US-20230061554-A1 | PROCESS FOR SYNTHESIS OF A 2-(5-ISOXAZOLYL)-PHENOL | FMC CORPORATION | 2023-03-02 | — | — | US | disclosed |
| WO-2003105850-A1 | 2-AMINOQUINOLINES AS MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONISTS | ABBOTT LABORATORIES (US) | 2003-12-24 | — | — | WO | disclosed |
| US-20030191156-A1 | Beta3 adrenergic agonists | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT | 2003-10-09 | — | — | US | disclosed |
| WO-2003080545-A2 | SUBSTITUTED PHENYLACETIC ACIDS | METABOLEX, INC. (US) | 2003-10-02 | — | — | WO | disclosed |
| CN-1441800-A | β3Adrenergic agonists | LILLY CO ELI (US) | 2003-09-10 | — | — | CN | disclosed |
| EP-1303509-A1 | BETA3 ADRENERGIC AGONISTS | ELI LILLY AND COMPANY (US) | 2003-04-23 | — | — | EP | disclosed |
| WO-2002006276-A1 | BETA3 ADRENERGIC AGONISTS | ELI LILLY AND COMPANY (US) | 2002-01-24 | — | — | WO | disclosed |
| US-4514214-A | Herbicidal sulfamates | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1985-04-30 | — | — | US | disclosed |
| US-4475944-A | PLANT GROWTH REGULATORS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1984-10-09 | — | — | US | disclosed |
| EP-0096593-A2 | Herbicidal sulfamates | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1983-12-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230061554-A1 | PROCESS FOR SYNTHESIS OF A 2-(5-ISOXAZOLYL)-PHENOL | CYP4F11, CYP2F1, CYP1A2 | EPHX2 1002/4885SMN1; SMN2 3236/4885ALDH1A1 268/4885 |
| US-20030191156-A1 | Beta3 adrenergic agonists | ADRB3, ADRB1, ADRB2 | EPHX2 1462/4885SMN1; SMN2 2177/4885ALDH1A1 1255/4885 |
| US-12291525-B2 | Process for synthesis of a 2-(5-isoxazolyl)-phenol | CYP4F11, CYP2F1, CYP1A2 | EPHX2 1002/4885SMN1; SMN2 3236/4885ALDH1A1 268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.